Antibiotic Rotation for Febrile Neutropenic Patients with Hematological Malignancies: Clinical Significance of Antibiotic Heterogeneity

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Chong, Yong ^a   Shimoda, Shinji ^a   Yakushiji, Hiroko ^b   Ito, Yoshikiyo ^b   Miyamoto, Toshihiro ^a   Kamimura, Tomohiko ^b   Shimono, Nobuyuki ^c   Akashi, Koichi ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b HARASANSHIN HOSPITAL   (Japan)

^c KYUSHU UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFEPIME; CIPROFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BLOOD CULTURE; CONTROLLED STUDY; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; FEBRILE NEUTROPENIA; FECES CULTURE; FEMALE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEMATOLOGIC MALIGNANCY; HUMAN; INFECTION CONTROL; JAPAN; LEUKEMIA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; PROGNOSIS; PROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; BETA-LACTAM RESISTANCE; CEPHALOSPORINS; CIPROFLOXACIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; FEVER; GRAM-NEGATIVE BACTERIAL INFECTIONS; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEUTROPENIA; PENICILLANIC ACID; PIPERACILLIN; PROSPECTIVE STUDIES; THIENAMYCINS;

NEGIBACTERIA;

EID: 84872808464     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0054190     Document Type: Article

References (34)

1. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, et al. (2002) 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34: 730-751.
2. Link H, Bohme A, Cornely OA, Hoffken K, Kellner O, et al. (2003) Antimicrobial therapy of unexplained fever in neutropenic patients-guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society). Ann Hematol 82 Suppl 2: S105-117.
3. Chong Y, Yakushiji H, Ito Y, Kamimura T, (2010) Cefepime-resistant Gram-negative bacteremia in febrile neutropenic patients with hematological malignancies. Int J Infect Dis 14 Suppl 3: e171-175.
4. Kollef MH, Ward S, Sherman G, Prentice D, Schaiff R, et al. (2000) Inadequate treatment of nosocomial infections is associated with certain empiric antibiotic choices. Crit Care Med 28: 3456-3464.
5. Raymond DP, Pelletier SJ, Crabtree TD, Gleason TG, Hamm LL, et al. (2001) Impact of a rotating empiric antibiotic schedule on infectious mortality in an intensive care unit. Crit Care Med 29: 1101-1108.
6. Gruson D, Hilbert G, Vargas F, Valentino R, Bui N, et al. (2003) Strategy of antibiotic rotation: long-term effect on incidence and susceptibilities of Gram-negative bacilli responsible for ventilator-associated pneumonia. Crit Care Med 31: 1908-1914.
7. Barie PS, Hydo LJ, Shou J, Larone DH, Eachempati SR, (2005) Influence of antibiotic therapy on mortality of critical surgical illness caused or complicated by infection. Surg Infect (Larchmt) 6: 41-54.
8. Bennett KM, Scarborough JE, Sharpe M, Dodds-Ashley E, Kaye KS, et al. (2007) Implementation of antibiotic rotation protocol improves antibiotic susceptibility profile in a surgical intensive care unit. J Trauma 63: 307-311.
9. Raineri E, Crema L, Dal Zoppo S, Acquarolo A, Pan A, et al. (2010) Rotation of antimicrobial therapy in the intensive care unit: impact on incidence of ventilator-associated pneumonia caused by antibiotic-resistant Gram-negative bacteria. Eur J Clin Microbiol Infect Dis 29: 1015-1024.
10. Warren DK, Hill HA, Merz LR, Kollef MH, Hayden MK, et al. (2004) Cycling empirical antimicrobial agents to prevent emergence of antimicrobial-resistant Gram-negative bacteria among intensive care unit patients. Crit Care Med 32: 2450-2456.
11. Evans HL, Milburn ML, Hughes MG, Smith RL, Chong TW, et al. (2005) Nature of gram-negative rod antibiotic resistance during antibiotic rotation. Surg Infect (Larchmt) 6: 223-231.
12. Brown EM, Nathwani D, (2005) Antibiotic cycling or rotation: a systematic review of the evidence of efficacy. J Antimicrob Chemother 55: 6-9.
13. Kollef MH, (2006) Is antibiotic cycling the answer to preventing the emergence of bacterial resistance in the intensive care unit? Clin Infect Dis 43 Suppl 2: S82-8.
14. Bal AM, Kumar A, Gould IM, (2010) Antibiotic heterogeneity: from concept to practice. Ann N Y Acad Sci 1213: 81-91.
15. Bradley SJ, Wilson AL, Allen MC, Sher HA, Goldstone AH, et al. (1999) The control of hyperendemic glycopeptide-resistant Enterococcus spp. on a haematology unit by changing antibiotic usage. J Antimicrob Chemother 43: 261-266.
16. Dominguez EA, Smith TL, Reed E, Sanders CC, Sanders WE Jr, (2000) A pilot study of antibiotic cycling in a hematology-oncology unit. Infect Control Hosp Epidemiol 21: S4-8.
17. Craig M, Cumpston AD, Hobbs GR, Devetten MP, Sarwari AR, et al. (2007) The clinical impact of antibacterial prophylaxis and cycling antibiotics for febrile neutropenia in a hematological malignancy and transplantation unit. Bone Marrow Transplant 39: 477-482.
18. Cadena J, Taboada CA, Burgess DS, Ma JZ, Lewis JS 2nd, et al. (2007) Antibiotic cycling to decrease bacterial antibiotic resistance: a 5-year experience on a bone marrow transplant unit. Bone Marrow Transplant 40: 151-155.
19. Hashino S, Morita L, Kanamori H, Takahata M, Onozawa M, et al. (2011) Clinical impact of cycling the administration of antibiotics for febrile neutropenia in Japanese patients with hematological malignancy. Eur J Clin Microbiol Infect Dis 31: 173-178.
20. Ramphal R, (2004) Changes in the etiology of bacteremia in febrile neutropenic patients and the susceptibilities of the currently isolated pathogens. Clin Infect Dis 39 Suppl 1: S25-31.
21. Chong Y, Yakushiji H, Ito Y, Kamimura T, (2011) Clinical impact of fluoroquinolone prophylaxis in neutropenic patients with hematological malignancies. Int J Infect Dis 15: e277-781.
22. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, et al. (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis 52: e56-93.
23. Bergstrom CT, Lo M, Lipsitch M, (2004) Ecological theory suggests that antimicrobial cycling will not reduce antimicrobial resistance in hospitals. Proc Natl Acad Sci U S A 101: 13285-13290.
24. National Committee for Clinical Laboratory Standards (2004) Performance Standards for Antimicrobial Susceptibility Testing. 14th Informational Supplement. Wayne, Pennsylvania: NCCLS.
25. Puzniak LA, Mayfield J, Leet T, Kollef M, Mundy LM, (2001) Acquisition of vancomycin-resistant enterococci during scheduled antimicrobial rotation in an intensive care unit. Clin Infect Dis 33: 151-157.
26. Ramphal R, Ambrose PG, (2006) Extended-spectrum beta-lactamases and clinical outcomes: current data. Clin Infect Dis 42 Suppl 4: S164-172.
27. Rahal JJ, Urban C, Horn D, Freeman K, Segal-Maurer S, et al. (1998) Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA 280: 1233-1237.
28. Lee SO, Lee ES, Park SY, Kim SY, Seo YH, et al. (2004) Reduced use of third-generation cephalosporins decreases the acquisition of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae. Infect Control Hosp Epidemiol 25: 832-837.
29. Brahmi N, Blel Y, Kouraichi N, Lahdhiri S, Thabet H, et al. (2006) Impact of ceftazidime restriction on gram-negative bacterial resistance in an intensive care unit. J Infect Chemother 12: 190-194.
30. Kim JY, Sohn JW, Park DW, Yoon YK, Kim YM, et al. (2008) Control of extended-spectrum {beta}-lactamase-producing Klebsiella pneumoniae using a computer-assisted management program to restrict third-generation cephalosporin use. J Antimicrob Chemother 62: 416-421.
31. Rodriguez-Bano J, Navarro MD, Romero L, Muniain MA, de Cueto M, et al. (2006) Bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge. Clin Infect Dis 43: 1407-1414.
32. Rodriguez-Bano J, Picon E, Gijon P, Hernandez JR, Ruiz M, et al. (2010) Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis. Clin Infect Dis 50: 40-48.
33. Gudiol C, Calatayud L, Garcia-Vidal C, Lora-Tamayo J, Cisnal M, et al. (2010) Bacteraemia due to extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome. J Antimicrob Chemother 65: 333-341.
34. Takesue Y, Nakajima K, Ichiki K, Ishihara M, Wada Y, et al. (2010) Impact of a hospital-wide programme of heterogeneous antibiotic use on the development of antibiotic-resistant Gram-negative bacteria. J Hosp Infect 75: 28-32.